The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1457383
Computational Insights into the Inhibitory Mechanism of Type 2 Diabetes Mellitus by Bioactive Components of Oryza sativa L. indica (Black rice)
Provisionally accepted- 1 Atta-ur-Rahman School of Applied Biosciences, National University of Sciences & Technology, Islamabad, Islamabad, Pakistan
- 2 National Agricultural Research Center, Islamabad, Islamabad, Pakistan
- 3 Research Center for Modeling and Simulation, National University of Sciences and Technology, Islamabad, Islamabad, Pakistan
Background: Type 2 Diabetes Mellitus is metabolic disease and is categorized by hyperglycemia, resistance to insulin and ß-cell dysfunction. Around the globe, about 422 million people have diabetes and out of which 1.5 million die annually. In spite of innovative advancements in field of diabetes, no biological drug has been known to successfully cure and avert its progression.Thereupon, natural drugs derived from plants are emerging as novel therapeutic strategy to combat diseases like diabetes.Objective: Current study aims to investigate antidiabetic potential of natural compounds of Oryza sativa L. indica (black rice) in disease treatment.Methods: Anti-oxidant activity and alpha amylase assays were performed to evaluate therapeutic potential of the extract. Gas Chromatography-Mass Spectrometry (GC-MS) was used for identification of constituents from the ethanol extract. ADMET profiling (absorption, distribution, metabolism, excretion and toxicity), network pharmacology and molecular dynamics simulation were employed in order to uncover the active ingredients and their therapeutic targets in Oryza sativa L. indica against type 2 diabetes mellitus.Results: GC-MS of plant extract provided total list of 184 compounds. Lipinski filter and toxicity parameters screened out 18 compounds. The topological parameter of Protein-Protein Interaction (PPI) were used to shortlist the 9 key proteins (STAT3, HSP90AA1, AKT1, SRC, ESR1, MAPK1, NFKB1, EP300, and CREBBP) in the type 2 diabetes mellitus pathways. Later, molecular docking analysis and simulations has shown that C14 (1H-Purine-8-propanoic acid, .alpha.-amino-2, 3, 6, 7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-) and C18 (Cyclohexane-carboxamide, N-furfuryl) bind with AKT1 and ESR1 with binding energy of 8.1, 6.9, 7.3 and 7.2 kcal/mol, respectively. RMSD (root mean square deviation) and RMSF (root mean square fluctuation) values for AKT1 and ESR1 has shown very little fluctuation, it indicated that proteins were stabilized after ligand docking.The study shows therapeutic drug candidates against AKT1 and ESR1 to treat type 2 diabetes mellitus. However, further wet-lab analysis is required to find out the best remedy for type 2 diabetes mellitus.
Keywords: Diabetes Mellitus, Type 2, Oryza, Network Pharmacology, molecular dynamics simulations, Insulin, Drug Discovery
Received: 30 Jun 2024; Accepted: 28 Aug 2024.
Copyright: © 2024 Rasool, Bhatti, Satti, Paracha and John. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Attya Bhatti, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences & Technology, Islamabad, 44000, Islamabad, Pakistan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.